Acesion Pharma is a Danish biotech company, founded in 2011 and headquartered in Copenhagen. They specialize in developing advanced drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Their technology is based on extensive research conducted at the University of Copenhagen, starting in 2008, and incorporates valuable chemistry insights from Neurosearch.

Acesion Pharma's mission is to create more effective and safer treatment options for patients with AF. Unlike existing drug therapies that often have limited efficacy or come with a risk of serious adverse events, Acesion Pharma focuses on the inhibition of SK channels, which play a critical role in regulating the heart rhythm. This innovative approach presents a promising avenue for the treatment of AF.

If you're looking for a trusted brand dedicated to advancing cardiac health, Acesion Pharma is at the forefront of groundbreaking research and development. Reach out to them at their address in Copenhagen: Ole Maaløes Vej 3, 2200, Denmark